Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Taimed's Conference May 31 of 2021
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by stock38on Jun 03, 2021 4:32am
150 Views
Post# 33317218

RE:RE:Taimed's Conference May 31 of 2021

RE:RE:Taimed's Conference May 31 of 2021 THANKS TO SPCEO/QWERTY /SCARLET /JEFFM
FOR YOUR COMMETNS on MY QUESTIONS.
 
        Especially appreciate Spceo for your great answers para by
    para in detail and Qwerty’s sharp analysis of the market
    structure.  I believe all Taimed’s investors will benefit from your
    answers.  For your explanations make us understand better of      where we  stand and where Trogarzo stands in the market.
    Really appreciate your interpretations, by the way, I would like
    to  ask Spceo one more question. How do you think about the
    peak sales of 1500 patients as per Taimed’s CEO mentioned in
    the conference. I estimated roughly that till Feb. of 2021 the
    number was around 300. How many patients right now
    according to your estimation. Is it possible to reach 1500, for
    how long it takes?

Thanks again for your responses
  Stock 38 from Taiwan

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities